# Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)

> **NCT01048879** · PHASE4 · COMPLETED · sponsor: **University of Michigan** · enrollment: 15 (actual)

## Conditions studied

- Critically Ill Renal Failure Requiring CVVHD and Oseltamivir
- Critically Ill Requiring ECMO and Oseltamivir

## Interventions

- **PROCEDURE:** pharmacokinetic blood sampling
- **PROCEDURE:** pharmacokinetic blood and dialysate sampling

## Key facts

- **NCT ID:** NCT01048879
- **Lead sponsor:** University of Michigan
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2012-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01048879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01048879, "Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01048879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*